Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Super-selective intracoronary injection of Rho-kinase inhibitor relieves refractory coronary vasospasms: a case report.

Taniguchi Y, Funayama H, Matsuda J, Fujita K, Nakagawa T, Nakamura T, Umemoto T, Mitsuhashi T, Ako J, Momomura S.

Int J Cardiol. 2014 Sep;176(1):270-1. doi: 10.1016/j.ijcard.2014.06.096. Epub 2014 Jul 8. No abstract available.

PMID:
25065335
2.

Intraradial administration of fasudil inhibits augmented Rho kinase activity to effectively dilate the spastic radial artery during coronary artery bypass grafting surgery.

Takagi T, Okamoto Y, Tomita S, Sato A, Yamaguchi S, Takuwa Y, Watanabe G.

J Thorac Cardiovasc Surg. 2011 Aug;142(2):e59-65. doi: 10.1016/j.jtcvs.2011.01.055. Epub 2011 Mar 12.

3.

Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery.

Inokuchi K, Ito A, Fukumoto Y, Matoba T, Shiose A, Nishida T, Masuda M, Morita S, Shimokawa H.

J Cardiovasc Pharmacol. 2004 Sep;44(3):275-7.

PMID:
15475822
4.

[Inhibition of Rho-kinase by fasudil preventing anginal attacks associated with spastic angina: a case report].

Hiroki J, Fukumoto Y, Shimokawa H, Hirooka Y, Takeshita A.

J Cardiol. 2004 Oct;44(4):161-4. Japanese.

PMID:
15532247
5.

Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm.

Dong M, Yan BP, Yu CM.

Cardiovasc Hematol Agents Med Chem. 2009 Oct;7(4):322-30. Review.

PMID:
19607644
6.

A new class of drug for pulmonary arterial hypertension. Can a Rho-kinase inhibitor break the stagnation in treating it?

Miyagawa K, Emoto N.

Circ J. 2013;77(10):2477-8. Epub 2013 Aug 9. No abstract available.

7.

Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.

Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A.

J Am Coll Cardiol. 2003 Jan 1;41(1):15-9.

8.

Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina.

Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A.

Circulation. 2002 Apr 2;105(13):1545-7.

9.

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.

Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H.

Heart. 2005 Mar;91(3):391-2. No abstract available.

10.

Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat.

Badejo AM Jr, Dhaliwal JS, Casey DB, Gallen TB, Greco AJ, Kadowitz PJ.

Am J Physiol Lung Cell Mol Physiol. 2008 Nov;295(5):L828-36. doi: 10.1152/ajplung.00042.2008. Epub 2008 Aug 8.

11.

[Basic and clinical studies on coronary vasospasm].

Hoka S, Shimokawa H.

Masui. 2002 Dec;51 Suppl:S151-7. Review. Japanese. No abstract available.

PMID:
12655726
12.

Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina.

Fukumoto Y, Mohri M, Inokuchi K, Ito A, Hirakawa Y, Masumoto A, Hirooka Y, Takeshita A, Shimokawa H.

J Cardiovasc Pharmacol. 2007 Mar;49(3):117-21.

PMID:
17414222
13.

Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm.

Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, Kuwata K, Kandabashi T, Egashira K, Ikegaki I, Asano T, Kaibuchi K, Takeshita A.

Cardiovasc Res. 1999 Sep;43(4):1029-39.

14.

Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo.

Shimokawa H, Morishige K, Miyata K, Kandabashi T, Eto Y, Ikegaki I, Asano T, Kaibuchi K, Takeshita A.

Cardiovasc Res. 2001 Jul;51(1):169-77.

15.

Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm.

Shibuya M, Asano T, Sasaki Y.

Acta Neurochir Suppl. 2001;77:201-4. Review. No abstract available.

PMID:
11563286
16.

[Fasudil(Rho-kinase inhibitor)].

Fukumoto Y.

Nihon Rinsho. 2011 Nov;69 Suppl 9:402-7. Japanese. No abstract available.

PMID:
22724237
17.

Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina.

Otsuka T, Ibuki C, Suzuki T, Ishii K, Yoshida H, Kodani E, Kusama Y, Atarashi H, Kishida H, Takano T, Mizuno K.

Coron Artery Dis. 2008 Mar;19(2):105-10. doi: 10.1097/MCA.0b013e3282f3420c.

PMID:
18300747
18.

Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage.

Satoh S, Takayasu M, Kawasaki K, Ikegaki I, Hitomi A, Yano K, Shibuya M, Asano T.

J Pharmacol Sci. 2012;118(1):92-8. Epub 2011 Dec 21.

19.

Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.

Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H.

Heart Vessels. 2010 Mar;25(2):144-9. doi: 10.1007/s00380-009-1176-8. Epub 2010 Mar 26.

PMID:
20339976
20.

Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits.

Sugiyama T, Shibata M, Kajiura S, Okuno T, Tonari M, Oku H, Ikeda T.

Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):64-9. doi: 10.1167/iovs.10-5265.

PMID:
20720232
Items per page

Supplemental Content

Write to the Help Desk